Search
COVID-19: Zydus Cadila gets DGCI nod for phase 3 clinical trials with biological therapy
- Drug firm Zydus Cadila said it has received the approval from the Drugs Controller General of India to start phase 3 clinical trials with its biological therapy PegiHep in COVID-19 patients.
- The company had completed the phase 2 clinical trials with PegiHep last month.
- The trials, which will commence in Dec , will be conducted on 250 patients across 20-25 centres in India, according to the filing.